Filtered By:
Cancer: Adenocarcinoma
Therapy: Neoadjuvant Radiation Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 211 results found since Jan 2013.
Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial
DISCUSSION: This trial will help define the best neoadjuvant treatment sequence for borderline resectable PDAC and aims to evaluate if a total neoadjuvant treatment integrating iHD-SBRT improves the patients' oncological outcomes.TRIAL REGISTRATION: The study was registered at ClinicalTrails.gov (NCT05083247) on October 19th, 2021, and in the Clinical Trials Information System (CTIS) EU CT database (2022-501181-22-01) on July 2022.PMID:37735634 | DOI:10.1186/s12885-023-11327-x
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Christelle Bouchart Julie Navez Ivan Borbath Karen Geboes Timon Vandamme Jean Closset Luigi Moretti Pieter Demetter Marianne Paesmans Jean-Luc Van Laethem Source Type: research
Selection of patients with pancreatic adenocarcinoma who may benefit from radiotherapy
Radiat Oncol. 2023 Aug 18;18(1):137. doi: 10.1186/s13014-023-02328-y.ABSTRACTDespite combination chemotherapy demonstrating a positive effect on survival, the clinical outcomes of pancreatic adenocarcinoma (PDAC) remain poor. Radiotherapy was previously a component of the curative treatment of PDAC. Advances in imaging and computer sciences have enabled the prescription of higher dosage of radiation focused on tumours with minimal toxicity to normal tissue. However, the role of radiotherapy has not been established in the curative treatment of localized PDAC because of the conflicting results from large prospective trials....
Source: Cancer Control - August 18, 2023 Category: Cancer & Oncology Authors: I-Shiow Jan Hui Ju Ch'ang Source Type: research
Increased toxicities associated with dose escalation of stereotactic body radiation therapy in prostate cancer: results from a phase I/II study
CONCLUSIONS: An SBRT dose of 35 Gy per 5 fractions is less likely to cause adverse events in patients with PCa than 375- and 40-Gy SBRT doses. Higher doses of SBRT should be applied with caution.PMID:37203203 | DOI:10.1080/0284186X.2023.2213443
Source: Acta Oncologica - May 19, 2023 Category: Cancer & Oncology Authors: Takero Hirata Osamu Suzuki Keisuke Otani Akimitsu Miyake Keisuke Tamari Yuji Seo Fumiaki Isohashi Naoki Kai Koji Hatano Kazutoshi Fujita Motohide Uemura Ryoichi Imamura Setsuo Tamenaga Yutaro Yoshino Yasutoshi Fumimoto Yasuo Yoshioka Norio Nonomura Kazuhi Source Type: research
Current State and Future Directions of Radiation Therapy for Pancreas Adenocarcinoma
Surg Oncol Clin N Am. 2023 Jul;32(3):399-414. doi: 10.1016/j.soc.2023.02.001. Epub 2023 Apr 4.ABSTRACTStudies suggest select patients from across the pancreatic adenocarcinoma (PDAC) disease spectrum may benefit from adding radiation therapy (RT) to multi-modality care. In resectable PDAC, there is an evolving role for neoadjuvant RT with adjuvant RT reserved for patients with increased recurrence risk. In borderline resectable PDAC, neoadjuvant chemoradiation likely improves R0 resection rates and in unresectable PDAC, definitive RT may prolong survival for some patients. Recent developments in RT delivery are promising b...
Source: The Surgical Clinics of North America - May 14, 2023 Category: Surgery Authors: Sujana Gottumukkala Samer Salamekh Nina N Sanford Source Type: research
